Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The new results helped boost Moderna’s stock by more than 4% in early trading June 30, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Everest Medicines unveils breakthroughs in AI+mRNA platform, reinforces global leadership in next-gen mRNA innovation: Hong Kong Monday, July 7, 2025, 10:00 Hrs [IST] Everest Medi ...

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

The author says the action creates mistrust of the committee’s vaccine recommendations and further increases patients’ and ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...